In their letter, Dr. Georgalas et al point to the potential complications of delayed wound healing and hypotony after trabeculectomy for NVG when it is combined with the use of MMC and anti-VEGF injections. The authors themselves report a case of severe hypotony and bleb leak after intravitreal injection of ranibizumab. Injecting anti-VEGF drugs in eyes with already existent avascular blebs may be rarely associated with bleb leak and hypotony. However, in the immediate postoperative period after trabeculectomy, the blebs are relatively more vascularized and have a greater healing response. Trabeculectomy alone has poor success rates in NVG eyes and has to be performed with adjunctive MMC. In our study, injection bevacizumab was given using the intracameral route prior to trabeculectomy. The half-life of bevacizumab in intraocular tissues is not more than 4 days and hence the effect of bevacizumab on bleb vascularity is not expected to last very long (1) (although there are no randomized studies to prove this). We administered bevacizumab injections prior to trabeculectomy with mitomycin. Our study eyes had fewer rates of complications compared to NVG eyes operated without bevacizumab. None of the study eyes in our series developed persistent hypotony. Intraocular injections of bevacizumab are now being increasingly used as an adjunct to filtering surgery for NVG with no reports of persistent hypotony in the postoperative period (2-5). In fact, Fakhraie et al report 39% failure to achieve intraocular pressure <21 mm Hg after trabeculectomy with MMC where intravitreal bevacizumab was administered preceding the surgery (4).This indicates that many cases of NVG remain refractory to this treatment. We agree with Georgalas et al that further long-term randomized prospective studies are needed to confirm the observations in our study and those reported by others.
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